List of Excipients in Branded Drug TRIAZOLAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	TRIAZOLAM	triazolam	16590-236	DOCUSATE SODIUM
STAT RX USA LLC	TRIAZOLAM	triazolam	16590-236	FD&C BLUE NO. 2
STAT RX USA LLC	TRIAZOLAM	triazolam	16590-236	LACTOSE
STAT RX USA LLC	TRIAZOLAM	triazolam	16590-236	MAGNESIUM STEARATE

Generic Drugs Containing TRIAZOLAM

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	triazolam	0054-4858	ANHYDROUS LACTOSE
Hikma Pharmaceuticals USA Inc	triazolam	0054-4858	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	triazolam	0054-4858	DOCUSATE SODIUM/SODIUM BENZOATE
Hikma Pharmaceuticals USA Inc	triazolam	0054-4858	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in TRIAZOLAM?

# Of NDCs	Excipient
6	ANHYDROUS LACTOSE
13	CELLULOSE, MICROCRYSTALLINE
1	CI 42090
3	D&C RED NO. 27

Excipient Strategy and Commercial Opportunities for Triazolam

Last updated: March 1, 2026

What are the key excipient considerations for Triazolam formulation?

Triazolam is a short-acting benzodiazepine used to treat insomnia. Its formulation targets rapid onset of action and bioavailability. Excipient selection affects stability, absorption, and patient tolerability.

Common excipients in Triazolam formulations:

• Fillers: Lactose monohydrate, microcrystalline cellulose.
• Binders: Polyvinylpyrrolidone (PVP).
• Disintegrants: Croscarmellose sodium.
• Lubricants: Magnesium stearate.
• Coatings: Hydroxypropyl methylcellulose (HPMC) or ethylcellulose for controlled release, or film-coatings for taste masking and stability.

Formulation considerations:

• Solubility and bioavailability: Triazolam's lipophilicity influences excipient choice to enhance absorption.
• Stability: Protects against hydrolysis or oxidative degradation; antioxidants may be added.
• Rapid disintegration: Essential for immediate-release formulations.

How does excipient strategy impact commercial opportunities?

Excipient innovation can extend patent life, improve product performance, or facilitate alternative delivery routes, opening multiple commercial avenues:

1. Enhanced Formulation Patents

Introducing novel excipients or combinations can yield patent extensions, delaying generic competition. For example, patents on controlled-release matrices or taste-masked coatings hold potential value.

2. Bioavailability Improvements

Formulations that increase bioavailability through excipient modifications can support lower dosing, reducing side effects and dosage frequency. This feature can enable premium pricing.

3. Alternative Delivery Systems

Developing transdermal patches, nasal sprays, or orally disintegrating tablets often relies on excipient innovation. For example:

• Patches require permeability enhancers.
• Nasal sprays use mucoadhesive agents.
• Orally disintegrating tablets need fast-acting disintegrants.

These delivery routes expand patient accessibility, especially for populations with swallowing difficulties.

4. Extended Release and Controlled Delivery

Controlled-release formulations utilize specific excipients to modulate drug release:

• Hydrogel-based matrices
• Membrane-coated particles

Such formulations can justify higher price points and improve patient adherence.

5. Patent and Regulatory Incentives

Excipient modifications with demonstrated stability and safety can meet regulatory pathways like 505(b)(2) or biosimilar pathways, reducing approval times and costs.

What are the commercial challenges related to excipient strategies?

• Regulatory approval: Use of novel excipients may incur extensive safety evaluations.
• Manufacturing complexity: Advanced formulations may require new equipment or processes.
• Market acceptance: Clinicians prioritize proven formulations, making incremental innovations critical.
• Patent cliffs: Original patents for Triazolam may expire, increasing generic competition.

Market landscape overview

Strategy	Focus	Impact	Timeline
Patent extensions	Novel excipients/formulation patents	Extend exclusivity, delay generics	3-5 years
Bioavailability enhancements	Solubility and absorption mods	Support lower doses, reduce side effects	2-4 years
Alternative delivery systems	Transdermal, nasal, ODT	Broaden patient base, justify premium pricing	4-6 years
Controlled-release formulations	Modified-release matrices	Increase adherence, reduce dosing frequency	3-5 years

Regulatory and manufacturing considerations

• Regulatory pathways: 505(b)(2) approval often relies on existing safety data but requires detailed excipient characterization.
• Quality control: Excipient purity, consistency, and stability testing are critical.
• Supply chain: Dependency on specialized excipients may impact production scalability.

Key takeaways

• Excipient selection is central to optimizing Triazolam's absorption, stability, and patient experience.
• Innovation in excipient strategy supports differentiation, patent extension, and new delivery platforms.
• Advancing formulations for alternative administration routes broadens market potential.
• Regulatory pathways favor incremental excipient modifications with established safety profiles.
• Market success depends on balancing innovation with manufacturing feasibility and regulatory approval.

FAQs

Q1: Can novel excipients extend Triazolam's patent life?
A: Yes. Patents on formulations utilizing novel excipients can provide additional exclusivity periods.

Q2: Which excipient modifications improve bioavailability?
A: Incorporating solubility enhancers, such as surfactants or lipid-based carriers, can improve absorption.

Q3: Are there approved alternative delivery routes for Triazolam?
A: Currently, oral tablets are standard; nasally administered formulations are under research but not yet marketed.

Q4: How do controlled-release formulations affect patient compliance?
A: They can reduce dosing frequency, potentially improving adherence and reducing side effects.

Q5: What regulatory pathways facilitate excipient innovations?
A: The 505(b)(2) pathway allows modifications with existing safety data, expediting approval.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Modified-Release Dosage Forms.
[2] European Medicines Agency. (2021). Guideline on excipients in the label and package leaflet.
[3] Smith, J. A., & Lee, K. (2020). Excipient innovations in drug formulation. Journal of Pharmaceutical Sciences, 109(2), 527–536.